Abstract
Outbreak and rapid spread of coronavirus disease (COVID-19) caused by coronavirus acute respiratory syndrome (SARS-CoV-2) caused severe acute respiratory syndrome (SARS-CoV-2) that started in Wuhan, and has become a global problem because of the high rate of human-to-human transmission and severe respiratory infections. Because of high prevalence of SARS-CoV-2, which threatens many people worldwide, rapid diagnosis and simple treatment are needed. Genome editing is a nucleic acid-based approach to altering the genome by artificially changes in genetic information and induce irreversible changes in the function of target gene. Clustered, regularly interspaced short palindromic repeats (CRISPR/Cas) could be a practical and straightforward approach to this disease. CRISPR/Cas system contains Cas protein, which is controlled by a small RNA molecule to create a double-stranded DNA gap. Evidence suggested that CRISPR/Cas was also usable for diagnosis and treatment of SARS-CoV-2 infection. In this review study, we discoursed on application of CRISPR technology in detection and treatment of SARS-CoV-2 infection. Another aspect of this study was to introduce potential future problems in use of CRISPR/Cas technology.
Introduction
Coronavirus disease (COVID-19) was spread in December 2019 and was recognized as a zoonotic disease (; ). Severe acute respiratory syndrome (SARS) virus was detected in sputum samples in 2003, and advanced stages in fecal samples may have been transmitted to humans by an intermediate host such as bats and civets (; ). Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) can be transmitted from an unknown carrier to a healthy person who could infect many people. SARS-CoV-2 resulted in pneumonia in Wuhan, China, with various symptoms reported. The disease has developed into a pandemic (; ; ). Appropriate methods could treat and control the disease. CRISPR/Cas9 was first recognized as a microbial immune system through which these organisms acquire immunity to invading viruses and plasmids (). When the invaded foreign DNA enters the bacteria, it is cleaved by cas nuclease enzymes. A portion of the cleaved DNA is then placed between two repeating sequences at the CRISPR site. Here, it is called a spacer (; ). The spacer sequences are used as templates to generate short RNA sequences. These sequences direct the Cas protein to the invasive DNA. Once the Cas protein binds to the invasive DNA, the enzyme cuts the outer DNA sequence into both strands, creating the region of double-strand breaks (DSB) (; ; ) and the nucleotides at the DSB position change the structure or end codon in the gene. Non-homologous end-joining repair (NHEJ) or homology-directed repair (HDR) systems are induced to edit the genome to cut and cleave external DNA. These deletions and additions lead to a permanent change in the open reading frame (; ).
Some model systems, including mammalian cells, can efficiently cleave any complementary sequence to the gRNA and target and cleave the RNA. Targeted genome editing, often called CRISPR/Cas9, is increasingly recognized as an effective tool in medicine (; ). It can inactivate the SARS-CoV2 virus in mammalian cells by truncating the specific sequence of the virus. Cas proteins appear to help in detection and treatment of viral infections. They are introduced into the viral genome via guide RNAs and destroy it in the target regions (; ; ). However, more regular interaction and collaboration between virology and molecular biology is needed to achieve substantial results in the treatment of SARS-CoV-2 (). In this review, we first introduce general concept of CRISPR/Cas9. Then, we discuss potential challenges for treatment, and finally, we address prospects for CRISPR/Cas9-based antiviral strategies for SARS-CoV-2.
The coronavirus family (CoVs) contains many virus species, and these viruses can cause various diseases in birds, livestock, and humans (). Members of the family are spherical and have an approximate diameter of 125 nm. The spines protrude from the surface of the virion and give the virus a particular crown-like appearance (). There are four main structural proteins in coronavirus: Membrane (M), spikes (S), envelope (E), and nucleocapsid (N) proteins (Figure 1A). The spikes bind the virus to the host cell receptor (; ). Researchers have discovered human coronavirus receptors, such as angiotensin-converting enzyme 2 (ACE2) for SARS-CoV () and HCoV-NL63 () or aminopeptidase N (APN) for HCoV-229E (; ). ACE2, APN, and DDP4 are ectopeptidase enzymes with different functions expressed on the surface of various cell types, including those of the human respiratory tract. MERS-CoV has been shown to require a dipeptidyl peptidase-4 (DPP-4) surface receptor to enter the host cell. SARS-CoV-2 uses the endogenous enzyme angiotensin-converting enzyme 2 (ACE2) to enter host cells (; ). After binding to the appropriate receptor, a fusion of the virus and cell membrane occurs, and the viral genome is transferred to the host cell’s cytoplasm. In the host cell, the viral products are produced and assembled (). After the virus particles are assembled, they are transported to the cell surface by vesicles and released by exocytosis (). SARS-CoV-2 mainly infects epithelial cells in the lung but can also invade macrophages and dendritic cells (; ). The exact mechanism of lung injury caused by SARS-Cov-2 is still unknown (). Serologic evidence of SARS-CoV-2 infection was observed in some individuals at animal markets before the disease outbreak. Some animals have also been infected with SARS-CoV-2 viruses isolated from camels, Himalayan palm civets, and raccoon dogs (; ). Further evidence from phylogenetic analysis suggests that SARS-CoV-2 is bat-derived (; ), as the genetic similarity between SARS-CoV-2 and bat-SARS is greater than 95%. Bat-SARS has the potential to be transmitted to humans. Although the risk of transmission is lower, it is affected by bat SARS in an area (). Although one study has shown that SARS-CoV-2 is not a mosaic (), there is speculation about its heritability. The UK Medicines Agency has approved molnupiravir to treat mild to moderate COVID-19 in people with at least one risk factor for severe disease. Molnupiravir could cut the number of people who need to go to the hospital in half and reduce the number of deaths. However, the supply would not last long if it were given to everyone who is sick because the daily caseload is high. Use of the drug would likely be limited to those at the highest risk for disease complications, such as older adults with heart, lung, or kidney disease, diabetes, or cancer (; ). Vaccination is the most important method of epidemic control. The emergence of numerous SARS-CoV-2 variants that are less prone to disease- and vaccine-induced immunity threatens progress. Despite these ongoing threats, the efficacy of the SARS-CoV-2 vaccine provides a reason for optimism for 2021 (). SARS-CoV-2 neutralizing antibodies in the serum of cured patients can be recovered and reused if SARS-CoV-2 recurs (). Such antibodies will help protect individuals at high risk.
FIGURE 1
Application of CRISPR/Cas9 Technology in Current Virology
Host-virus conflict is a dynamic process. Viruses use host factors to complete their life cycle, and the host uses the body’s immune system to fight off the viral infection, so it does not waste energy. The virus must enter the host cell to replicate its genome and complete its life cycle () (Figure 1B). Theoretically, antiviral treatments can prevent the virus from entering the host cell or destroy the genetic elements of the virus. Targeting host factors can help the virus become resistant to antiviral drugs (). However, this hypothesis needs further investigation to identify its weaknesses and exploit them after these weaknesses have been addressed. The CRISPR/Cas9 system could be useful because it targets viral nucleic acid and host material quickly and conveniently (). Cas9 is known in CRISPR/Cas systems as a DNA endonuclease directed from a guide RNA (sgRNA) to the target DNA to alter the genome of the target region (; ). This genome editing leads to an antiviral status within the host cell. CRISPR/Cas9 was the first system studied in HIV-1 gene therapy research (). Host cell receptors, CCR5 and CXCR4, help HIV enter the host cell (; ). Therefore, one of the antiviral candidates to treat HIV is suppressing these receptors. Researchers have successfully suppressed the expression of CCR5 in primary CD4 T cells at an appropriate level using the CRISPR/Cas9 gene-editing system. These cells develop resistance to HIV-1 and do not cause extracellular toxicity (; ).
Host cell factors such as the Apo-Lipoprotein B Editing Complex (APOBEC3) and Tripartite Motif Containing 5 (TRIM5) have been identified as viral limiters for HIV infection (). APOBEC3 is thought to act as an antiviral agent by causing mutations in the viral genome. CRISPR/Cas9-based regulation of the host APOBEC3 factor reduces HIV reporter gene expression and provides antiviral effects (; ). Two specific amino acids in TRIM5 have made it an actual antiviral agent against HIV-1 infection. This antiviral candidate can induce cleavage of viral capsid proteins, demonstrating its antiviral properties (Sastri and Campbell, 2011; ). Therefore, TRIM5 may be a suitable target for the CRISPR/Cas9 system. Eliminating microRNA-146 by CRISPR/Cas9 resulted in a significant increase in HIV-1 limiting factors ().
Some host factors are essential for virus replication, assembly, and budding. Therefore, knocking out their genes could be an alternative to preventing HIV-1 infection (; ); such gene deletions can be performed using the CRISPR/Cas9 system (). Interestingly, these gene deletions have no significant effects on host cells (). These results demonstrate the antiviral potential of CRISPR/Cas9-based therapies, as it is possible to disrupt key host factors essential for HIV infection.
Application of CRISPR/Cas Technology in SARS-CoV-2
The worldwide pandemic of SARS and CoV-2 poses a significant threat to global public health and societal stability and has become a significant global public health problem. Regrettably, current diagnostic and therapeutic methods to prevent and control SARS-CoV-2 have many limitations. CRISPR/Cas technology has emerged as a potential complement to conventional methods in recent years. Biomedicine has extensively used biological tools based on the CRISPR/Cas systems. They are helpful in pathogen detection, clinical antiviral treatment, and drug and vaccine discovery. Therefore, CRISPR/Cas technology could be promising in preventing and treating SARS-CoV-2 and other emerging infectious diseases.
Application of CRISPR in the Detection of SARS-CoV-2
CRISPR-Cas systems could be used for molecular diagnosis of nucleic acids (Figure 2) (:; ). CRISPR-Cas-based diagnostic methods have the same sensitivity and specificity as conventional PCR. However, their cost is low because they do not require complex or expensive technology (). The application of CRISPR-Cas in molecular diagnostics could transform global diagnostic and healthcare systems (). The Cas proteins used in CRISPR-Cas systems vary depending on the DNA or RNA targeted and the intended applications (). Following the global spread of the COVID-19 pandemic, rapid and straightforward diagnostic techniques are in high demand. CRISPR-based methods, which have demonstrated superior detection capability in as little as 30–60 min, could overcome this obstacle. In addition, a CRISPR/Cas9-mediated lateral flow nucleic acid assay (CASLFA) has been developed to identify infections using the CRISPR/Cas system (). However, FDA approval is still pending. Regarding “collateral breast activity,” CRISPR-based diagnostic techniques have been developed using the Cas12a or Cas13 nuclease. The Cas12a/Cas13 nuclease, a component of the CRISPR tool, is activated after CRISPR RNA binds to the target bosome (crRNA). When produced, it non-specifically cleaves ssDNA/RNA particles in the vicinity and explicitly acts as a collateral bosome or transbosome. Researchers took advantage of this property to develop fluorescently labeled ssDNA/RNA press reporter probes capable of detecting visible bands in a paper strip via a side-stream assay, enabling the development of a novel nucleic acid-based diagnostic test (). Viral RNA targeting crRNA can activate Cas protein, resulting in collateral cleavage of press reporter probes and a helpful band on the paper strip (). In the newly developed Specific High-sensitivity Enzymatic Reporter Unlocking (SHERLOCK) technology, the activity of the crRNA-Cas13a protein complex is used to recognize RNA molecules and cut collateral RNA near the target RNAs. Metsky et al. have developed a website with CRISPR-Cas13-based assay designs for the detection of 67 diseases, including SARS-CoV-2, Zika virus, and dengue fever, with a choice of single or multiple panels (). The comprehensive SARS-CoV-2 diagnostic test is based on advanced technology from SHERLOCK. This technique uses fluorescently identified, non-targeted press reporter RNA (). SHERLOCK test for detecting SARS-CoV-2, which has a sensitivity of 10 copies per microliter and can be fluorescently confirmed, has been validated with counterfeit RNA fragments. This molecular analytical test should be inexpensive and provide rapid results. The DETECTOR is a similar technique used to amplify pathogenic DNA with RPA, and reverse transcription to identify RNA viruses is also used as a SHERLOCK system in this procedure. Cas12a-crRNA identifies the target and activates the Cas12a nuclease, which cleaves fluorescently labeled reporter sDNA without discrimination. In less than an hour, DETECTOR distinguished between human papillomavirus 16 (HPV16) and human papillomavirus 18 (HPV18) in pure DNA from cultured human cells and professional samples (). Broughton et al. diagnosed COVID -19 using two specific crRNAs targeting genes E and N and a discovery series ranging from 70 to 300 copies per microliter of sample material. They used LAMP with reverse transcription instead of RPA-based amplification to identify COVID -19 in less than 30 min. These CRISPR-Cas-based nucleic acid detection methods require independent amplification of nucleic acids. They require human activity, complicating detection and increasing the risk of spreading contamination (). Ding et al. developed the AIOD-CRISPR (All-In-One Dual CRISPR-Cas12a) assay method, which enables rapid visual detection of viral nucleic acids with high sensitivity and accuracy. In this article, all materials required for viral nucleic acid detection are incubated in a single pot at 37°C, which simplifies the process and minimizes the risk of contamination. With high sensitivity, SARS-CoV-2 genomic RNA was detected with the AIOD-CRISPR assay (). LED assay uses blue light illumination to image the tubes instead of a paper dipstick with sidestream detection. Scientists in India have identified the Francisella novicida Cas9 orthology (FnCas9) as sensitive to nuclear differences, and the Linked Attire Discovery Assay (FELUDA) for FnCas9 has been developed as a low-cost point-of-care (LCC) assay for identifying SARS-CoV-2 infections in the clinical setting ().
FIGURE 2
CRISPR’s Advantages in Detection of SARS-CoV-2
“Metagenomics” and “qRT-PCR” are two widely used molecular methods for identifying novel viruses (; ). Current qRT-PCR-based SARS-CoV-2 diagnostic methods are efficient and accurate for virus detection. Where qRT-PCR technology is not available, the virus can spread globally (). Finally, the diagnostic accuracy of many molecular methods has not yet been clarified. Although CRISPR/Cas has been a widely used gene-editing strategy since 2013, the simultaneous promiscuous cleavage tasks of a specific collection of Cas nucleases were discovered later and used to detect nucleic acids from artificial insemination (; ). Due to its exceptional sensitivity, specificity, and reliability, RNA-directed nucleic acid detection based on CRISPR/Cas nuclease has recently shown significant potential for developing next-generation molecular diagnostic technology (; ). For example, AIOD-CRISPR can detect only 1.2 copies of DNA targets and 4.6 documents of RNA targets in 40 min of incubation without preamplification when detecting SARS-CoV-2 (). CRISPR-nCoV has the same sensitivity and uniqueness as next-generation metagenomic sequencing (mNGS) in less than 40 min (). Some of the major advantages of this approach over existing techniques such as qRT-PCR are 1) uniformity of signal in a nucleus (e.g., SARS-CoV-2 guide RNAs can be distinguished from SARS-CoV and MERS-CoV at the N2 site) and 2) integration with low-cost portable reporting sheets and side streptometers. 3) isothermal signal amplification for rapid target detection in the absence of termocycling. CRISPR-based assays are more accessible and convenient than RT-PCR viral RNA identification assays because the CRISPR system does not require bulky instrumentation or complicated processes (). Most CRISPR-Cas-based detection methods require pre-amplifying a specific nucleic acid combination and manual procedures. These modifications will undoubtedly complicate procedures and impose costs on the environment. The following table summarizes the current studies on the diagnosis of SARS-CoV-2.
Sensitive and Specificity
CRISPR-based diagnostic assays show excellent clinical sensitivity and specificity (; ; ). To improve the sensitivity and specificity of CRISPR-based SARS-CoV-2 detection, different models were created. Selection of two crRNAs improved sensitivity () and increased resistance to viral RNA changes ().
In addition, several improvements have been made to increase the sensitivity of CRISPR-based SARS-CoV-2 detection experiments. These include modifying crRNA (), incorporating small particles to improve action kinetics (), improving reagent ratios (), increasing reagent concentration through careful focusing (), and increasing RNA input besides RNA quantity. Computational techniques ensure the sensitivity and specificity of amplification primers and crRNAs to detect SARS-CoV-2 (; ; ). Researchers developed customized CRISPR-based assays with sensitivity and specificity comparable to quantitative real-time PCR (qPCR) based on these findings. Incorporating the methods described above could help improve the overall sensitivity and specificity of COVID -19 CRISPR diagnostic tools.
Turn-Around Time
Several CRISPR-mediated COVID -19 diagnostic studies have used the same techniques as RT -qPCR to recover viral RNA, consistent with previous findings (; ). Unlike rapid RNA extraction techniques needed for point-of-care diagnostics, these methods are time-consuming. Therefore, several researchers have investigated whether CRISPR-based assays are feasible using rapid viral RNA extraction methods. When Joung and colleagues mixed the clinical samples with the Quick Extract solution, they incubated them at 95°C for 5 min before assaying them for viral RNA. Heat treatment and chemical reduction were performed as a 10-minute technique lysed the viral particles and inactivated the nucleases (). In one study, Ramachandran et al. used electric field-driven microfluidics to recover viral RNA in less than 5 min (). RT-qPCR to detect SARS-CoV-2 takes approximately 45 min if RNA extraction is omitted (). This result, considering that RT-qPCR is compatible with rapid RNA extraction methods, suggests that the time required for RNA extraction in CRISPR-based research equals that of RT-qPCR (). The time required for an essay varies depending on the subject. However, specific efficient procedures can be completed in less than 30 min (). Others require 40, 45, or 50–60 min without RNA extraction (; ). One study found that an automated CRISPR-based assay can be performed in 30 min (). CRISPR-based SARS-CoV-2 detection methods equal RT-qPCR in terms of assay time. RT-qPCR analyses require sending samples to a central laboratory. However, CRISPR-based diagnostics allow on-site detection, which drastically reduces reporting time.
Ease of Use
RT-qPCR experiments are performed as one-step reactions using master mixes to simplify them. A master mix containing both RT-LAMP and Cas12a-based detection reagents was developed by Joung and colleagues and proved stable after six freeze-thaw cycles (). Most CRISPR-based SARS-CoV-2 detection assays require two phases, but researchers have also developed one-step methods that require less time and effort (; ). A wide range of CRISPR-based assays can be performed using a single method, with RT-qPCR requiring less time or the same time as RT-PCR due to preparing the required reagents in master mixes. CRISPR-based assays are comparable to RT-qPCR in terms of ease of use. However, point-of-care assays require fewer manual activities and a lower level of technical skill. CRISPR-based assays are being developed that are both automated and sample-to-result ().
Requirement of Equipment
Since most CRISPR-based research uses isothermal techniques, a thermocycler is not required. So, it’s possible to use a normal heating block or water bath to perform the tests (; ). When using a lateral flow readout technique, no signal detection equipment is required. After DNA amplification, the reaction tube must be opened, which can lead to contamination and false-positive results in subsequent tests. Therefore, reading lateral flow strips requires a specific position or a closed cartridge. A fluorescence readout would be more appropriate. Although a plate reader primarily detects the fluorescent signal, many studies have shown that it can also be identified by eye examination under blue light (; ).
Viral RNA can be isolated from clinical samples using techniques that do not require complex or lengthy equipment for the CRISPR-based identification of SARS-CoV-2. Compared with traditional, labor-intensive RNA extraction techniques, these rapid extraction methods have the same () or slightly lower efficiency ().
Microfluidic devices that extract viral RNA and enable CRISPR-based detection can be used for automated or sample-to-result assays (). Researchers used a battery-powered, portable thermal cycler and fluorescence reader (). Finally, these examples demonstrate that tests to detect SARS-CoV-2 with CRISPR do not require expensive or complicated equipment. These tests can be performed in locations other than a central laboratory, such as airports, clinics, and other locations with limited resources.
Cost per Test
Although using lateral flow strips increases the cost per assay (), the total material cost for fluorescence-based CRISPR-mediated SARS-CoV-2 detection assays is lower than the material cost for RT -qPCR-based SARS-CoV-2 detection assays (; ). For example, the CRISPR-COVID assay costs less than $3.50 for a single reaction, depending on the assay technique (). On an industrial scale, the cost can be as low as $0.6 per pound (Gootenberg et al., 2020; ). In addition, CRISPR-based screening has reduced the cost of the first tool (). (). Fluorescence-based CRISPR-mediated COVID–19 analysis assays are less costly than RT–qPCR.
Application of CRISPR in SARS-CoV-2 Treatment
SARS-CoV-2 is a novel coronavirus of the positive-sense RNA virus family that infects the respiratory tract and causes disease through direct cytotoxic effects and the production of host cytokines (). The life cycle of SARS-CoV-2 is like that of other strongly associated coronaviruses, such as the virus that causes SARS. The virus spreads its RNA genome in the cell, synthesizes the genomic and subgenomic negative sense RNAs used in the viral mRNA, and produces a new copy of the viral positive sense genome (; ). While conventional vaccines recognize viral proteins or viruses by activating the human immune system and limiting viral entry into the cell (), the CRISPR-based approach is an alternative antiviral strategy to recognize and eliminate the viral genome and mRNAs within the cell. It should be possible to restrict viral replication to specific positives and viral mRNAs while destroying viral genome replication and gene expression templates. Therapeutic applications of CRISPR are on the rise. Technology plays an essential role in exploring potential therapies for various genetic diseases through direct modification of the genome ().
Besides DNA targeting Cas9, RNA targeting CRISPR-Cas13 is an antiviral approach against single-stranded RNA viruses such as lymphocytic choriomeningitis virus (LCMV), influenza A virus (IAV), and vesicular stomatitis virus (VSV) in human cells (). Conversely, Stanford College (CA, United States) researchers are working on CRISPR-based therapies for infectious diseases, using a different method and going beyond the human genome. When researchers worked on the flu virus, they followed in the footsteps of many others. They shifted the focus of their gene-targeted antiviral drug to COVID-19 and the pandemic (; ). It was reported that the prophylactic CRISPR antiviral approach in human lung epithelial cells (PAC-MAN) was identified as a potentially helpful new technique to stop viral traits and replication and that the PAC-MAN approach was identified as a type of genetic intervention to target SARS-CoV-2 and potentially all sequenced coronaviruses (Figure 3). Interestingly, a pool of crRNA suppressed about 70% of the reporter signal, demonstrating the potential of CRISPR PAC–MAN technology to degrade viral genetic material. In addition, several crRNAs targeting the entire conserved region of the SARS-RdRP CoV-2 and N-protein genes caused RNA degradation of over 80 and 90%, respectively.
FIGURE 3
To reprogram CRISPR-Cas13b against the genomic and subgenomic RNAs of SARS-CoV-2, we performed genome-wide computational predictions and screens at single-nucleotide resolution. Cas13b effectors reprogrammed to target accessible segments of spike and nucleocapsid transcripts had silencing efficiencies greater than 98 percent in virus-free animals. Tailored and multiplexed Cas13b CRISPR RNAs (crRNAs) inhibit viral replication in mammalian cells infected with replication-competent SARS-CoV-2, including novel dominant variants. CRISPR-Cas13-based viral suppression strategy is readily adaptable and can be extended to harmful viruses other than SARS-CoV-2 and, therefore, could provide an effective platform for antiviral treatments (). However, it is critical to identify and study the deleterious effects of using single-guide RNAs (sgRNAs), the CRISPR/Cas system, or PAC-MAN on host physiology. Although the Cas method seems to have a high chance of successfully identifying therapies, it needs further investigation.
However, it is critical to identify and investigate the deleterious effects of using single-guide RNAs (sgRNAs), the CRISPR/Cas system, or PAC-MAN on host physiology. Although the Cas method seems to have a high chance of successfully identifying therapies, it needs further investigation.
Limitation of CRISPR Technology
CRISPR technology is advancing rapidly. Although recently discovered and new, CRISPR/Cas is a tool with multiple genome engineering capabilities. Because of its ability to edit genomes in such a user-friendly way, it has attracted the attention of biomedical researchers. CRISPR can appropriately solve various viral diseases. In cell-based and animal studies, successful results have been achieved in several human viral infections (; ; ). The therapeutic use of CRISPR/Cas to treat human viral diseases has generally gained great importance (). However, gaining expertise in the diagnostic and therapeutic use of CRISPR/Cas in viral infections is associated with potential risks. Because this is a new science, we will briefly describe the limitations of CRISPR/Cas. We hope these limitations will be addressed, and an appropriate therapeutic and diagnostic system for SARS-CoV-2 will be developed. There are several legitimate concerns about CRISPR technology’s efficacy and technical limitations. According to research, both target and off-target editing provide limited and partial results, and CRISPR studies in animals and human cells have demonstrated these limitations (; ; ; ).
Although few studies have shown off-target editing and most studies support CRISPR/Cas, one of the major concerns associated with the CRISPR/Cas system is the possibility of off-target activity and mutant viruses. Viral escape mutations are caused by deletions (indels) at the Cas9 segregation site (). Using NHEJ repair system, Cas9 causes a mutation and renders the virus ineffective. Typically, NHEJ repair system repairs the damage (). However, a subset of these mutations can cause the virus to survive and escape, and viruses with such mutations are no longer interested in the original gRNA (). Thus, inappropriate mutations can occur with any virus. If these cells are infected with the mutant virus, they might resist CRISPR/Cas treatment. Therefore, the desired results may not be achieved. Non-mutated virus-infected cells may provide a viral reservoir for disease spread in subsequent disease episodes (). Therefore, CRISPR/Cas system is risky and not profitable in the antiviral market.
Transferring CRISPR/Cas9 to virus-infected cells is another limitation of this new method. The success of this technology in the clinical setting is necessary to control the most severe viral diseases, including SARS-CoV-2 (). As CRISPR becomes more efficient and sensitive, these concerns may become obsolete. Technology is advancing at an unprecedented pace.
Conclusion
Emerging viruses such as SARS-CoV-2 are responsible for hundreds of thousands of illnesses and deaths worldwide each year. The disease is spreading everywhere and destroying the economies of affected populations. Genome editing strategies to deactivate the viral genome could be a suitable way to treat such diseases. The lack of effective drugs and vaccines may be contributing to so many SARS-CoV-2 samples being collected for rapid diagnosis. Containing and preventing further spread of the virus appears to be critical, and rapid detection of infection in organisms may prevent further spread of the disease. CRISPR/Cas is a solution for treating virus-related diseases with many future applications. Therefore, the CRISPR/Cas9 system could be helpful, especially if some valuable and specific sgRNAs are developed. If the CRISPR/Cas system leads to therapeutic and diagnostic solutions, the financial burden will be reduced because CRISPR/Cas-based therapies will eliminate the need for drugs. In addition, the treated individual will not suffer repeated disease relapses. Therefore, advances in the CRISPR/Cas system and the success of clinical trials in animal models are critical Table 1, .
TABLE 1
| CRISPR/System | Sample type | Number of samples | Assay time | Platform | Specific/Sensitive | Country | References |
|---|---|---|---|---|---|---|---|
| CRISPR–Cas12a | respiratory swab | 36 | <40 min | DETECTR | — | United States | |
| CRISPR–Cas13a | nasopharyngeal swabs | 154 | >60 min | SHERLOCK | 100%/96% | Thailand | |
| CRISPR–Cas13a | nasopharyngeal swabs | 1808 | 110 min | CREST | 100%/88.8% | United States | |
| CRISPR–Cas13a | nasopharyngeal swabs | 50 | 50 min | SHINE | 100%/90% | United States | |
| CRISPR–Cas12b | nasopharyngeal or anterior nasal swab | 202 | <60 min | STOPCovid | 98.5%/93.1% | — | |
| CRISPR-Cas3 And CRISPR–Cas12a | nasopharyngeal and oropharyngeal swab | 31 | 40 min | CONAN | 95%/90% | Japan | |
| CRISPR–Cas12a | nasopharyngeal swabs, sputum, BAL | 378 | 30 min | DETECTR | 95.5%/93% | Dutch | |
| CRISPR/Cas12a | Clinical sample | 31 | 45 min | CRISPR/Cas12a-NER | 100%/100% | China | |
| CRISPR/Cas12a | raw nasopharyngeal swab | 8 | 35 min | ITP-CRISPR | 100%/75% | United States | |
| CRISPR/Cas12a | Pharyngeal swab, nasopharyngeal swabs | 295 | 60 min | SENA | 100%/100% | China | |
| CRISPR–Cas13a | nasopharyngeal swab, bronchoalveolar lavage fluid specimens | 114 | 40 min | CRISPR-COVID | 100%/100% | China |
Some CRISPR-based SARS-CoV-2 diagnostic studies.
BAL, broncheo-alvealar lavage.
Statements
Author contributions
BS, CBA, and AN developed the concept and designed the study. MAO, SH, and AI did a systematic search and prepared the first draft. All authors participated in the revising of the manuscript before submission.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AbbottT. R.DhamdhereG.LiuY.LinX.GoudyL.ZengL.et al (2020a). Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza. Cell181 (4), 865–876. 10.1016/j.cell.2020.04.020
2
AbbottT. R.DhamdhereG.LiuY.LinX.GoudyL.ZengL.et al (2020b).Development of CRISPR as a Prophylactic Strategy to Combat Novel Coronavirus and Influenza. BioRxiv. 10.1101/2020.03.13.991307
3
AckermanC. M.MyhrvoldC.ThakkuS. G.FreijeC. A.MetskyH. C.YangD. K.et al (2020). Massively Multiplexed Nucleic Acid Detection with Cas13. Nature582 (7811), 277–282. 10.1038/s41586-020-2279-8
4
AliZ.AmanR.MahasA.RaoG. S.TehseenM.MarsicT.et al (2020). iSCAN: An RT-LAMP-Coupled CRISPR-Cas12 Module for Rapid, Sensitive Detection of SARS-CoV-2. Virus. Res.288, 198129. 10.1016/j.virusres.2020.198129
5
AllocatiN.PetrucciA. G.Di GiovanniP.MasulliM.Di IlioC.De LaurenziV. (2016). Bat-man Disease Transmission: Zoonotic Pathogens from Wildlife Reservoirs to Human Populations. Cel Death Discov.2 (1), 1–8. 10.1038/cddiscovery.2016.48
6
AmanR.MahasA.ButtH.AljedaaniF.MahfouzM.MahfouzM. (2018). Engineering RNA Virus Interference via the CRISPR/Cas13 Machinery in Arabidopsis. Viruses10 (12), 732. 10.3390/v10120732
7
AndersenK. G.RambautA.LipkinW. I.HolmesE. C.GarryR. F. (2020). The Proximal Origin of SARS-CoV-2. Nat. Med.26 (4), 450–452. 10.1038/s41591-020-0820-9
8
Arizti-SanzJ.FreijeC. A.StantonA. C.PetrosB. A.BoehmC. K.SiddiquiS.et al (2020). Streamlined Inactivation, Amplification, and Cas13-Based Detection of SARS-CoV-2. Nat. Commun.11 (1), 1–9. 10.1038/s41467-020-19097-x
9
AyanoğluF. B.Elçi̇nA. E.Elçi̇nY. M. (2020). Bioethical Issues in Genome Editing by CRISPR-Cas9 Technology. Turk J. Biol.44 (2), 110–120. 10.3906/biy-1912-52
10
AzharE. I.El-KafrawyS. A.FarrajS. A.HassanA. M.Al-SaeedM. S.HashemA. M.et al (2014). Evidence for Camel-To-Human Transmission of MERS Coronavirus. N. Engl. J. Med.370 (26), 2499–2505. 10.1056/NEJMoa1401505
11
AzharM.PhutelaR.AnsariA. H.SinhaD.SharmaN.KumarM.et al (2020). Rapid, Field-Deployable Nucleobase Detection and Identification Using FnCas9. BioRxiv. 10.1101/2020.04.07.028167
12
BarrangouR.HorvathP. (2017). A Decade of Discovery: CRISPR Functions and Applications. Nat. Microbiol.2 (7), 1–9. 10.1038/nmicrobiol.2017.92
13
BawageS. S.TiwariP. M.SantangeloP. J. (2018). Synthetic mRNA Expressed Cas13a Mitigates RNA Virus Infections. bioRxiv, 370460. 10.1101/370460
14
BelouzardS.ChuV. C.WhittakerG. R. (2009). Activation of the SARS Coronavirus Spike Protein via Sequential Proteolytic Cleavage at Two Distinct Sites. Proc. Natl. Acad. Sci.106 (14), 5871–5876. 10.1073/pnas.0809524106
15
BeniacD. R.AndonovA.GrudeskiE.BoothT. F. (2006). Architecture of the SARS Coronavirus Prefusion Spike. Nat. Struct. Mol. Biol.13 (8), 751–752. 10.1038/nsmb1123
16
BogerdH. P.KornepatiA. V. R.MarshallJ. B.KennedyE. M.CullenB. R. (2015). Specific Induction of Endogenous Viral Restriction Factors Using CRISPR/Cas-derived Transcriptional Activators. Proc. Natl. Acad. Sci. USA112 (52), E7249–E7256. 10.1073/pnas.1516305112
17
BohaciakovaD.RenzovaT.FedorovaV.BarakM.Kunova BosakovaM.HamplA.et al (2017). An Efficient Method for Generation of Knockout Human Embryonic Stem Cells Using CRISPR/Cas9 System. Stem Cell Dev.26 (21), 1521–1527. 10.1089/scd.2017.0058
18
BrandsmaE.VerhagenH. J. M. P.van de LaarT. J. W.ClaasE. C. J.CornelissenM.van den AkkerE. (2020). Rapid, Sensitive and Specific SARS Coronavirus-2 Detection: A Multi-center Comparison between Standard qRT-PCR and CRISPR Based DETECTR. medRxiv. 10.1101/2020.07.27.20147249
19
BrinkmanE. K.ChenT.de HaasM.HollandH. A.AkhtarW.van SteenselB. (2018). Kinetics and Fidelity of the Repair of Cas9-Induced Double-Strand DNA Breaks. Mol. Cel.70 (5), 801–813. 10.1016/j.molcel.2018.04.016
20
BrokowskiC. (2018). Do CRISPR Germline Ethics Statements Cut it. CRISPR J.1 (2), 115–125. 10.1089/crispr.2017.0024
21
BroughtonJ. P.DengX.YuG.FaschingC. L.ServellitaV.SinghJ.et al (2020a). CRISPR-Cas12-based Detection of SARS-CoV-2. Nat. Biotechnol.38 (7), 870–874. 10.1038/s41587-020-0513-4
22
BroughtonJ. P.DengX.YuG.FaschingC. L.SinghJ.StreithorstJ.et al (2020b). Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-Based DETECTR Lateral Flow Assay. MedRxiv. 10.1101/2020.03.06.20032334
23
ChenJ. S.MaE.HarringtonL. B.Da CostaM.TianX.PalefskyJ. M.et al (2018a). CRISPR-Cas12a Target Binding Unleashes Indiscriminate Single-Stranded DNase Activity. Science360 (6387), 436–439. 10.1126/science.aar6245
24
ChenS.YuX.GuoD. (2018b). CRISPR-cas Targeting of Host Genes as an Antiviral Strategy. Viruses10 (1), 40. 10.3390/v10010040
25
CookJ. D.GrantE. H. C.ColemanJ. T. H.SleemanJ. M.RungeM. C. (2021). Risks Posed by SARS-CoV-2 to North American Bats during winter Fieldwork. Conservat Sci. Prac3, e410. 10.1111/csp2.410
26
CormanV. M.LandtO.KaiserM.MolenkampR.MeijerA.ChuD. K.et al (2020). Detection of 2019 Novel Coronavirus (2019-nCoV) by Real-Time RT-PCR. Eurosurveillance25 (3), 2000045. 10.2807/1560-7917.ES.2020.25.3.2000045
27
CreechC. B.WalkerS. C.SamuelsR. J. (2021). SARS-CoV-2 Vaccines. JAMA325 (13), 1318–1320. 10.1001/jama.2021.3199
28
De Silva FeelixgeH. S.StoneD.RoychoudhuryP.AubertM.JeromeK. R. (2018). CRISPR/Cas9 and Genome Editing for Viral Disease-Is Resistance Futile. ACS Infect. Dis.4 (6), 871–880. 10.1021/acsinfecdis.7b00273
29
DingX.YinK.LiZ.LiuC. (2020). All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and Visual Detection of Novel Coronavirus SARS-CoV-2 and HIV Virus. BioRxiv. 10.1101/2020.03.19.998724
30
DolanA. E.HouZ.XiaoY.GramelspacherM. J.HeoJ.HowdenS. E.et al (2019). Introducing a Spectrum of Long-Range Genomic Deletions in Human Embryonic Stem Cells Using Type I CRISPR-Cas. Mol. Cel.74 (5), 936–950. 10.1016/j.molcel.2019.03.014
31
DrostenC.GüntherS.PreiserW.Van Der WerfS.BrodtH.-R.BeckerS.et al (2003). Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. N. Engl. J. Med.348 (20), 1967–1976. 10.1056/NEJMoa030747
32
DuL.HeY.ZhouY.LiuS.ZhengB.-J.JiangS. (20092009). The Spike Protein of SARS-CoV - a Target for Vaccine and Therapeutic Development. Nat. Rev. Microbiol.7 (3), 226–236. 10.1038/nrmicro2090
33
FarehM.ZhaoW.HuW.CasanJ. M. L.KumarA.SymonsJ.et al (2021). Reprogrammed CRISPR-Cas13b Suppresses SARS-CoV-2 Replication and Circumvents its Mutational Escape through Mismatch Tolerance. Nat. Commun.12 (1), 1–16. 10.1038/s41467-021-24577-9
34
FehrA. R.PerlmanS. (2015). Coronaviruses: Methods and Protocols, Methods in Molecular Biology. New York: Springer Science, Business Media New York1282, 1–23.
35
FreijeC. A.MyhrvoldC.BoehmC. K.LinA. E.WelchN. L.CarterA.et al (2019). Programmable Inhibition and Detection of RNA Viruses Using Cas13. Mol. Cel.76 (5), 826–837. 10.1016/j.molcel.2019.09.013
36
FungS.-Y.YuenK.-S.YeZ.-W.ChanC.-P.JinD.-Y. (2020). A Tug-Of-War between Severe Acute Respiratory Syndrome Coronavirus 2 and Host Antiviral Defence: Lessons from Other Pathogenic Viruses. Emerging Microbes & Infections9 (1), 558–570. 10.1080/22221751.2020.1736644
37
GanbaatarU.LiuC. (2021). CRISPR-based COVID-19 Testing: Toward Next-Generation Point-of-Care Diagnostics. Front. Cel. Infect. Microbiol.11, 663949. 10.3389/fcimb.2021.663949
38
GarneauJ. E.DupuisM.-È.VillionM.RomeroD. A.BarrangouR.BoyavalP.et al (2010). The CRISPR/Cas Bacterial Immune System Cleaves Bacteriophage and Plasmid DNA. Nature468 (7320), 67–71. 10.1038/nature09523
39
GilaniU.ShaukatM.RasheedA.ShahidM.TasneemF.ArshadM.et al (2019). The Implication of CRISPR/Cas9 Genome Editing Technology in Combating Human Oncoviruses. J. Med. Virol.91 (1), 1–13. 10.1002/jmv.25292
40
GootenbergJ. S.AbudayyehO. O.LeeJ. W.EssletzbichlerP.DyA. J.JoungJ.et al (2017). Nucleic Acid Detection with CRISPR-Cas13a/C2c2. Science356 (6336), 438–442. 10.1126/science.aam9321
41
GrahamR. L.BaricR. S. (2010). Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission. J. Virol.84 (7), 3134–3146. 10.1128/JVI.01394-09
42
GuW.MillerS.ChiuC. Y. (2019). Clinical Metagenomic Next-Generation Sequencing for Pathogen Detection. Annu. Rev. Pathol. Mech. Dis.14, 319–338. 10.1146/annurev-pathmechdis-012418-012751
43
GuanW.-j.NiZ.-y.HuY.LiangW.-h.OuC.-q.HeJ.-x.et al (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med.382 (18), 1708–1720. 10.1056/NEJMoa2002032
44
GuanghuiT.GongJ.KanL.ZhangX.HeY.PanJ.et al (2020). A General Onepot-Method for Nucleic Acid Detection with CRISPR-Cas12a. 10.21203/rs.3.rs-44613/v1
45
GuoL.SunX.WangX.LiangC.JiangH.GaoQ.et al (2020). SARS-CoV-2 Detection with CRISPR Diagnostics. Cell Discov6 (1), 1–4. 10.1038/s41421-020-0174-y
46
GuoX.LiX.-J. (2015). Targeted Genome Editing in Primate Embryos. Cell Res25 (7), 767–768. 10.1038/cr.2015.64
47
HarringtonL. B.BursteinD.ChenJ. S.Paez-EspinoD.MaE.WitteI. P.et al (2018). Programmed DNA Destruction by Miniature CRISPR-Cas14 Enzymes. Science362 (6416), 839–842. 10.1126/science.aav4294
48
HouP.ChenS.WangS.YuX.ChenY.JiangM.et al (2015). Genome Editing of CXCR4 by CRISPR/cas9 Confers Cells Resistant to HIV-1 Infection. Sci. Rep.5 (1), 1–2. 10.1038/srep15577
49
HouT.ZengW.YangM.ChenW.RenL.AiJ.et al (2020). Development and Evaluation of a Rapid CRISPR-Based Diagnostic for COVID-19. Plos Pathog.16 (8), e1008705. 10.1371/journal.ppat.1008705
50
HsuP. D.LanderE. S.ZhangF. (2014). Development and Applications of CRISPR-Cas9 for Genome Engineering. Cell157 (6), 1262–1278. 10.1016/j.cell.2014.05.010
51
HuangW.YuL.WenD.WeiD.SunY.ZhaoH.et al (2020a). A CRISPR-Cas12a-Based Specific Enhancer for More Sensitive Detection of SARS-CoV-2 Infection. EBioMedicine61, 103036. 10.1016/j.ebiom.2020.103036
52
HuangZ.TianD.LiuY.LinZ.LyonC. J.LaiW.et al (2020b). Ultra-sensitive and High-Throughput CRISPR-P Owered COVID-19 Diagnosis. Biosens. Bioelectron.164, 112316. 10.1016/j.bios.2020.112316
53
IngramS. P.WarmenhovenJ. W.HenthornN. T.SmithE. A. K.ChadwickA. L.BurnetN. G.et al (2019). Mechanistic Modelling Supports Entwined rather Than Exclusively Competitive DNA Double-Strand Break Repair Pathway. Sci. Rep.9 (1), 1–3. 10.1038/s41598-019-42901-8
54
IshinoY.KrupovicM.ForterreP. (2018). History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology. J. Bacteriol.200 (7), e00580–17. 10.1128/JB.00580-17
55
JernP.RussellR. A.PathakV. K.CoffinJ. M. (2009). Likely Role of APOBEC3G-Mediated G-To-A Mutations in HIV-1 Evolution and Drug Resistance. Plos Pathog.5 (4), e1000367. 10.1371/journal.ppat.1000367
56
JiaF.LiX.ZhangC.TangX. (2020). The Expanded Development and Application of CRISPR System for Sensitive Nucleotide Detection. Protein Cell11 (9), 624–629. 10.1007/s13238-020-00708-8
57
JinekM.ChylinskiK.FonfaraI.HauerM.DoudnaJ. A.CharpentierE. (2012). A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science337 (6096), 816–821. 10.1126/science.1225829
58
JoungJ.LadhaA.SaitoM.KimN.-G.WoolleyA. E.SegelM.et al (2020a). Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing. N. Engl. J. Med.383 (15), 1492–1494. 10.1056/NEJMc2026172
59
JoungJ.LadhaA.SaitoM.SegelM.BruneauR.HuangM.-l. W.et al (2020b). Point-of-care Testing for COVID-19 Using SHERLOCK Diagnostics. MedRxiv. 10.1101/2020.05.04.20091231
60
KaminskiM. M.AbudayyehO. O.GootenbergJ. S.ZhangF.CollinsJ. J. (2021). CRISPR-based Diagnostics. Nat. Biomed. Eng.5 (7), 643–656. 10.1038/s41551-021-00760-7
61
KellnerM. J.KoobJ. G.GootenbergJ. S.AbudayyehO. O.ZhangF. (2019). SHERLOCK: Nucleic Acid Detection with CRISPR Nucleases. Nat. Protoc.14 (10), 2986–3012. 10.1038/s41596-019-0210-2
62
KennedyE. M.CullenB. R. (2015). Bacterial CRISPR/Cas DNA Endonucleases: A Revolutionary Technology that Could Dramatically Impact Viral Research and Treatment. Virology479-480, 213–220. 10.1016/j.virol.2015.02.024
63
KleinH. L.BačinskajaG.CheJ.CheblalA.ElangoR.EpshteinA.et al (2019). Guidelines for DNA Recombination and Repair Studies: Cellular Assays of DNA Repair Pathways. Microb. Cel6 (1), 1–64. 10.15698/mic2019.01.664
64
LadhaA.JoungJ.AbudayyehO. O.GootenbergJ. S.ZhangF. (2020). A 5-min RNA Preparation Method for COVID-19 Detection with RT-qPCR. MedRxiv. 10.1101/2020.05.07.20055947
65
LauS. K. P.WooP. C. Y.LiK. S. M.HuangY.TsoiH.-W.WongB. H. L.et al (2005). Severe Acute Respiratory Syndrome Coronavirus-like Virus in Chinese Horseshoe Bats. Proc. Natl. Acad. Sci.102 (39), 14040–14045. 10.1073/pnas.0506735102
66
LiC.GuanX.DuT.JinW.WuB.LiuY.et al (2015). Inhibition of HIV-1 Infection of Primary CD4+ T-Cells by Gene Editing of CCR5 Using Adenovirus-Delivered CRISPR/Cas9. J. Gen. Virol.96 (8), 2381–2393. 10.1099/vir.0.000139
67
LiF.LiW.FarzanM.HarrisonS. C. (2005). Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor. Science309 (5742), 1864–1868. 10.1126/science.1116480
68
LiQ.QinZ.WangQ.XuT.YangY.HeZ. (2019). Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy. Comput. Struct. Biotechnol. J.17, 689–698. 10.1016/j.csbj.2019.05.006
69
LinJ.-Y.NagyP. D. (2013). Identification of Novel Host Factors via Conserved Domain Search: Cns1 Cochaperone Is a Novel Restriction Factor of Tombusvirus Replication in Yeast. J. Virol.87 (23), 12600–12610. 10.1128/jvi.00196-13
70
LinK.GallayP. (2013). Curing a Viral Infection by Targeting the Host: the Example of Cyclophilin Inhibitors. Antivir. Res.99 (1), 68–77. 10.1016/j.antiviral.2013.03.020
71
LinoC. A.HarperJ. C.CarneyJ. P.TimlinJ. A. (2018). Delivering CRISPR: a Review of the Challenges and Approaches. Drug Deliv.25 (1), 1234–1257. 10.1080/10717544.2018.1474964
72
LiuJ.ZhengX.TongQ.LiW.WangB.SutterK.et al (2020). Overlapping and Discrete Aspects of the Pathology and Pathogenesis of the Emerging Human Pathogenic Coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J. Med. Virol.92 (5), 491–494. 10.1002/jmv.25709
73
LuciaC.FedericoP.-B.AlejandraG. C. (2020). An Ultrasensitive, Rapid, and Portable Coronavirus SARS-CoV-2 Sequence Detection Method Based on CRISPR-Cas12. BioRxiv. 10.1101/2020.02.29.971127
74
MahaseE. (2021). Covid-19: UK Becomes First Country to Authorise Antiviral Molnupiravir.
75
MakarovaK. S.WolfY. I.AlkhnbashiO. S.CostaF.ShahS. A.SaundersS. J.et al (2015). An Updated Evolutionary Classification of CRISPR-Cas Systems. Nat. Rev. Microbiol.13 (11), 722–736. 10.1038/nrmicro3569
76
MetskyH. C.FreijeC. A.Kosoko-ThoroddsenT.-S. F.SabetiP. C.MyhrvoldC. (2020). CRISPR-based Surveillance for COVID-19 Using Genomically-Comprehensive Machine Learning Design. BioRxiv. 10.1101/2020.02.26.967026
77
MiłekJ.Blicharz-DomańskaK. (2018). Coronaviruses in Avian Species - Review with Focus on Epidemiology and Diagnosis in Wild Birds. J. Vet. Res.62 (3), 249–255. 10.2478/jvetres-2018-0035
78
MocarskiE. S.ShenkT.PassR. F. (2020). in Cytomegaloviruses. Fields Virology. Editor KnipeD. M. (Howley PM.
79
MonteilV.KwonH.PradoP.HagelkrüysA.WimmerR. A.StahlM.et al (2020). Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell181 (4), 905–913. 10.1016/j.cell.2020.04.004
80
MyhrvoldC.FreijeC. A.GootenbergJ. S.AbudayyehO. O.MetskyH. C.DurbinA. F.et al (2018). Field-deployable Viral Diagnostics Using CRISPR-Cas13. Science360 (6387), 444–448. 10.1126/science.aas8836
81
NeumanB. W.AdairB. D.YoshiokaC.QuispeJ. D.OrcaG.KuhnP.et al (2006). Supramolecular Architecture of Severe Acute Respiratory Syndrome Coronavirus Revealed by Electron Cryomicroscopy. J. Virol.80 (16), 7918–7928. 10.1128/jvi.00645-06
82
NguyenL. T.SmithB. M.JainP. K. (2020). Enhancement of Trans-cleavage Activity of Cas12a with Engineered crRNA Enables Amplified Nucleic Acid Detection. Nat. Commun.11 (1), 1–3. 10.1038/s41467-020-18615-1
83
OoiK. H.TayJ. W. D.TeoS. Y.LiuM. M.KaewsapsakP.JinS.et al (2020). A CRISPR-Based SARS-CoV-2 Diagnostic Assay that Is Robust against Viral Evolution and RNA Editing. bioRxiv. 10.1101/2020.07.03.185850
84
ParaskevisD.KostakiE. G.MagiorkinisG.PanayiotakopoulosG.SourvinosG.TsiodrasS. (2020). Full-genome Evolutionary Analysis of the Novel corona Virus (2019-nCoV) Rejects the Hypothesis of Emergence as a Result of a Recent Recombination Event. Infect. Genet. Evol.79, 104212. 10.1016/j.meegid.2020.104212
85
PatchsungM.JantarugK.PattamaA.AphichoK.SuraritdechachaiS.MeesawatP.et al (2020). Clinical Validation of a Cas13-Based Assay for the Detection of SARS-CoV-2 RNA. Nat. Biomed. Eng.4 (12), 1140–1149. 10.1038/s41551-020-00603-x
86
PengR.LinG.LiJ. (2016). Potential Pitfalls of CRISPR/Cas9-mediated Genome Editing. Febs J.283 (7), 1218–1231. 10.1111/febs.13586
87
RajV. S.MouH.SmitsS. L.DekkersD. H. W.MüllerM. A.DijkmanR.et al (2013). Dipeptidyl Peptidase 4 Is a Functional Receptor for the Emerging Human Coronavirus-EMC. Nature495 (7440), 251–254. 10.1038/nature12005
88
RamachandranA.HuykeD. A.SharmaE.SahooM. K.HuangC.BanaeiN.et al (2020). Electric Field-Driven Microfluidics for Rapid CRISPR-Based Diagnostics and its Application to Detection of SARS-CoV-2. Proc. Natl. Acad. Sci. USA117 (47), 29518–29525. 10.1073/pnas.2010254117
89
RappuoliR. (2018). Glycoconjugate Vaccines: Principles and Mechanisms. Sci. Transl. Med.10 (456), eaat4615. 10.1126/scitranslmed.aat4615
90
RathD.AmlingerL.RathA.LundgrenM. (2015). The CRISPR-Cas Immune System: Biology, Mechanisms and Applications. Biochimie117, 119–128. 10.1016/j.biochi.2015.03.025
91
RauchJ. N.ValoisE.SolleyS. C.BraigF.LachR. S.AudouardM.et al (2021). A Scalable, Easy-To-Deploy Protocol for Cas13-Based Detection of SARS-CoV-2 Genetic Material. J. Clin. Microbiol.59 (4), e02402–20. 10.1128/jcm.02402-20
92
Rodríguez-RodríguezD.Ramírez-SolísR.Garza-ElizondoM.Garza-RodríguezM. a.Barrera-SaldaíaH. (2019). Genome Editing: A Perspective on the Application of CRISPR/Cas9 to Study Human Diseases (Review). Int. J. Mol. Med.43 (4), 1559–1574. 10.3892/ijmm.2019.4112
93
Santos-CostaQ.LopesM. M.CaladoM.Azevedo-PereiraJ. M. (2014). HIV-2 Interaction with Cell Coreceptors: Amino Acids within the V1/V2 Region of Viral Envelope Are Determinant for CCR8, CCR5 and CXCR4 Usage. Retrovirology11 (1), 1–7. 10.1186/s12977-014-0099-3
94
SastriJ.CampbellE. M. (2011). Recent Insights into the Mechanism and Consequences of TRIM5α Retroviral Restriction. AIDS Res. Hum. retroviruses27 (3), 231–238. 10.1089/aid.2010.0367
95
ScheufeleD. A.XenosM. A.HowellE. L.RoseK. M.BrossardD.HardyB. W. (2017). U.S. Attitudes on Human Genome Editing. Science357 (6351), 553–554. 10.1126/science.aan3708
96
ShmakovS. A.SitnikV.MakarovaK. S.WolfY. I.SeverinovK. V.KooninE. V. (2017). The CRISPR Spacer Space Is Dominated by Sequences from Species-specific Mobilomes. MBio8 (5), e01397–17. 10.1128/MBIO.01397-17
97
SicardA.PirollesE.GalletR.VernereyM.-S.YvonM.UrbinoC.et al (2019). A Multicellular Way of Life for a Multipartite Virus. Elife8, e43599. 10.7554/eLife.43599
98
StraitonJ. (2019). Genetically Modified Humans: the X-Men of Scientific Research. BioTechniques66 (6), 249–252. 10.2144/btn-2019-0056
99
TengY.LuoM.YuT.ChenL.HuangQ.ChenS.et al (2019). CRISPR/Cas9-mediated Deletion of miR-146a Enhances Antiviral Response in HIV-1 Infected Cells. Genes Immun.20 (4), 327–337. 10.1038/s41435-018-0036-x
100
WangL.-F.EatonB. T. (2007). “Bats, Civets and the Emergence of SARS,” in Wildlife and Emerging Zoonotic Diseases: The Biology, Circumstances and Consequences of Cross-Species Transmission, 325–344. 10.1007/978-3-540-70962-6_13
101
WangX.ZhongM.LiuY.MaP.DangL.MengQ.et al (2020). Rapid and Sensitive Detection of COVID-19 Using CRISPR/Cas12a-based Detection with Naked Eye Readout, CRISPR/Cas12a-NER. Sci. Bull.65 (17), 1436–1439. 10.1016/j.scib.2020.04.041
102
WeatherleyD. A. V.BoswellM. T.Rowland-JonesS. L. (2017). Targeting TRIM5α in HIV Cure Strategies for the CRISPR-Cas9 Era. Front. Immunol.8, 1616. 10.3389/fimmu.2017.01616
103
WeiY.TernsR. M.TernsM. P. (2015). Cas9 Function and Host Genome Sampling in Type II-A CRISPR-Cas Adaptation. Genes Dev.29 (4), 356–361. 10.1101/gad.257550.114
104
WeinheimerV. K.BecherA.TonniesM.HollandG.KnepperJ.BauerT. T.et al (2012). Influenza A Viruses Target Type II Pneumocytes in the Human Lung. J. Infect. Dis.206 (11), 1685–1694. 10.1093/infdis/jis455
105
WilenC. B.TiltonJ. C.DomsR. W. (2012). HIV: Cell Binding and Entry. Cold Spring Harbor Perspect. Med.2 (8)–a006866. 10.1101/cshperspect.a006866
106
WrappD.WangN.CorbettK. S.GoldsmithJ. A.HsiehC.-L.AbionaO.et al (2020). Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. Science367 (6483), 1260–1263. 10.1126/science.abb2507
107
WuC.LiuY.YangY.ZhangP.ZhongW.WangY.et al (2020a). Analysis of Therapeutic Targets for SARS-CoV-2 and Discovery of Potential Drugs by Computational Methods. Acta Pharmaceutica Sinica B10 (5), 766–788. 10.1016/j.apsb.2020.02.008
108
WuD.WuT.LiuQ.YangZ. (2020b). The SARS-CoV-2 Outbreak: what We Know. Int. J. Infect. Dis.94, 44–48. 10.1016/j.ijid.2020.03.004
109
WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.et al (2020c). A New Coronavirus Associated with Human Respiratory Disease in China. Nature579 (7798), 265–269. 10.1038/s41586-020-2008-3
110
WuK.LiW.PengG.LiF. (2009). Crystal Structure of NL63 Respiratory Coronavirus Receptor-Binding Domain Complexed with its Human Receptor. Proc. Natl. Acad. Sci.106 (47), 19970–19974. 10.1073/pnas.0908837106
111
XiaoQ.GuoD.ChenS. (2019). Application of CRISPR/Cas9-based Gene Editing in HIV-1/AIDS Therapy. Front. Cel. Infect. Microbiol.9, 69. 10.3389/fcimb.2019.00069
112
XiaoY.LuoM.DolanA. E.LiaoM.KeA. (2018). Structure Basis for RNA-Guided DNA Degradation by Cascade and Cas3. Science361 (6397), eaat0839. 10.1126/science.aat0839
113
XuK.NagyP. D. (2015). RNA Virus Replication Depends on Enrichment of Phosphatidylethanolamine at Replication Sites in Subcellular Membranes. Proc. Natl. Acad. Sci. USA112 (14), E1782–E1791. 10.1073/pnas.1418971112
114
YeagerC. L.AshmunR. A.WilliamsR. K.CardellichioC. B.ShapiroL. H.LookA. T.et al (1992). Human Aminopeptidase N Is a Receptor for Human Coronavirus 229E. Nature357 (6377), 420–422. 10.1038/357420a0
115
YoshimiK.TakeshitaK.YamayoshiS.ShibumuraS.YamauchiY.YamamotoM.et al (2020). Rapid and Accurate Detection of Novel Coronavirus SARS-CoV-2 Using CRISPR-Cas3. SSRN J. 10.2139/ssrn.3640844
116
ZhengJ. (2020). SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. Int. J. Biol. Sci.16 (10), 1678–1685. 10.7150/ijbs.45053
117
ZhouF.YuT.DuR.FanG.LiuY.LiuZ.et al (2020). Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: a Retrospective Cohort Study. The lancet395 (10229), 1054–1062. 10.1016/S0140-6736(20)30566-3
118
ZhouG.ZhaoQ. (2020). Perspectives on Therapeutic Neutralizing Antibodies against the Novel Coronavirus SARS-CoV-2. Int. J. Biol. Sci.16 (10), 1718–1723. 10.7150/ijbs.45123
119
ZhouJ.ChuH.ChanJ. F.-W.YuenK.-Y. (2015). Middle East Respiratory Syndrome Coronavirus Infection: Virus-Host Cell Interactions and Implications on Pathogenesis. Virol. J.12 (1), 1–7. 10.1186/s12985-015-0446-6
120
ZischewskiJ.FischerR.BortesiL. (2017). Detection of On-Target and Off-Target Mutations Generated by CRISPR/Cas9 and Other Sequence-specific Nucleases. Biotechnol. Adv.35 (1), 95–104. 10.1016/j.biotechadv.2016.12.003
Summary
Keywords
coronaviruses, SARS-CoV-2, CRISPR/Cas9, gene editing, ACE-2 receptors
Citation
Shademan B, Nourazarian A, Hajazimian S, Isazadeh A, Biray Avci C and Oskouee MA (2022) CRISPR Technology in Gene-Editing-Based Detection and Treatment of SARS-CoV-2. Front. Mol. Biosci. 8:772788. doi: 10.3389/fmolb.2021.772788
Received
08 September 2021
Accepted
21 December 2021
Published
11 January 2022
Volume
8 - 2021
Edited by
William C. Cho, QEH, Hong Kong SAR, China
Reviewed by
Xianding Deng, University of California, San Francisco, United States
Luigi Santacroce, University of Bari Aldo Moro, Italy
Nur Izzah Ismail, The Chinese University of Hong Kong, China
Updates
Copyright
© 2022 Shademan, Nourazarian, Hajazimian, Isazadeh, Biray Avci and Oskouee.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Cigir Biray Avci, Cigir.biray@ege.edu.tr, orcid.org/0000-0002-2748-3124; Mahin Ahangar Oskouee, ahangar1342@gmail.com
This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.